Japanese Drug Store Chain Sugi Holdings Acquires TMRC’s CRO Business
This article was originally published in PharmAsia News
Executive Summary
Japan drug store chain Sugi Holdings will acquire Tokyo-based bioventure company TMRC's contract clinical research business. The two agreed March 16 that TMRC will spin off the CRO business to form TMRC CRO by March 31, and Sugi's wholly owned CRO business wing Sugi Medical will acquire 100 percent of Tmrc CRO shares. Sugi Holdings subsidiary Sugi Medical Research is also scheduled to join the merged company June 1. Sugi Medical expanded into the CRO business in Japan through acquiring Fuji Biomedics's CRO section last year. (Click here for more - Japanese language